HANP infusion therapy for early infants with congestive heart failure after surgical repair

• Published in: Kyobu geka. The Japanese journal of thoracic surgery Vol. 54; no. 10; p. 853
• Main Authors: Hamawaki, M, Tomino, T, Sato, H, Imura, M, Suzuki, T, Nakashima, K, Okamoto, Y
• Format: Journal Article
• Language: Japanese
• Published: Japan 01.09.2001
• Subjects: Atrial Natriuretic Factor - therapeutic use; Heart Defects, Congenital - surgery; Heart Failure - drug therapy; Heart Failure - etiology; Hemodynamics; Humans; Hypertension, Pulmonary - complications; Infant; Infant, Newborn; Infusions, Intravenous; Postoperative Period
• ISSN: 0021-5252

We report about successful case of human atrial natriuretic peptide (HANP) infusion therapy for early infants who developed congestive heart failure after surgical repair of congenital heart diseases at Ehime Prefectural Central Hospital between January, 1998 through January, 2000. Age at operation ranged from 0 day to 38 days (mean 20 days), and body weight ranged from 1.6 kg to 3.5 kg (2.8 kg as mean). Following HANP infusion at incremental doses of 0.05 to 0.24 microgram/kg/min (0.16 microgram/kg/min as mean), urine output and hemodynamics dramatically improved. Urine output increased from 0.75 ml/kg/hr to 2.79 ml/kg/hr (p = 0.0001) and good urinary output was maintained (3.06 ml/kg/hr) even after discontinuation of the infusion. During the infusion, the heart rate decreased from 157 bpm to 150 bpm and the systemic systolic blood pressure increased from 68 mmHg to 78 mmHg. Central venous pressure decreased from 9.3 mmHg to 7.9 mmHg. There were no adverse effects by HANP infusion. These are successful cases of HANP infusion therapy as the initial treatment of post-operative pulmonary hypertension in this age group. Human atrial natriuretic peptide infusion therapy can be used safely and might be useful in some early infants with CHF, although more investigation is needed.